Your prediction
Carbylan Therapeutics Inc Stock
Carbylan Therapeutics Inc shows a slight decrease today, losing -€0.100 (-0.800%) compared to yesterday.
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Carbylan Therapeutics Inc stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of Carbylan Therapeutics Inc in the next few years
Pros
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
?
C******** o* t** e**********
Cons
?
B****
?
S********** s********
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Carbylan Therapeutics Inc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Carbylan Therapeutics Inc | -0.800% | 4.167% | -1.575% | 38.122% | -1.575% | 76.007% | -63.873% |
| Pharma Mar S.A. | 0.460% | 1.121% | -4.661% | -20.846% | 1.927% | 27.833% | -36.083% |
| Clinuvel Pharmaceuticals | 12.420% | -1.005% | -11.785% | -7.980% | -9.413% | -58.238% | -54.253% |
| Cicassia Pharmaceuticals | 1.440% | -5.442% | -9.740% | 2.963% | -4.795% | 49.784% | 159.328% |
News
KalVista Posts 154% Expense Jump in Q1
KalVista Pharmaceuticals (NASDAQ:KALV), a biopharmaceutical company developing and commercializing therapies for rare diseases, announced its earnings for the first quarter of fiscal 2026 on Sept
